| Business Summary | | Celgene
Corporation
is
a
biopharmaceutical
company
engaged
primarily
in
the
discovery,
development
and
commercialization
of
orally
administered,
small-molecule
drugs
for
the
treatment
of
cancer
and
inflammatory
diseases,
via
gene
regulation.
The
Company
has
developed
and
integrated
a
large
set
of
proprietary
target
and
drug
discovery
technologies
to
accelerate
the
application
of
genomics
to
the
discovery
of
new
classes
of
gene-regulating
drugs.
The
Company's
drug
discovery
and
development
programs
are
focused
in
several
disease
areas
in
which
gene
dysregulation
plays
a
major
role
in
the
onset
and
progression
of
disease,
including
cancer
and
inflammatory
diseases. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Celgene
is
a
specialty
company
engaged
in
the
development
and
commercialization
of
orally
administered,
small
molecule
drugs
for
the
treatment
of
cancer
and
immunological
diseases.
For
the
six
months
ended
6/30/01,
revenues
rose
34%
to
$46.3
million.
Net
loss
fell
82%
to
$2.3
million.
Results
reflect
increased
use
of
THALOMID
by
oncologists,
the
amortization
of
up-front
payments
on
two
agreements
with
Novartis
and
improved
gross
margins. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| John Jackson, 56 Chairman,
CEO | $739K | $26.5M | Sol Barer, Ph.D., 54 Pres,
COO | 517K | 12.9M | Robert Hugin, 46 Sr.
VP and CFO | 417K | 4.9M | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|